Why the study?
T2DM involves alterations in lipid metabolism beyond conventional cholesterol profiles, motivating investigation into whether specific plasma lipidomic signatures relate to PCAT inflammation and CAD burden.
Are circulating lysophosphatidylethanolamine species associated with pericoronary adipose tissue inflammation and coronary atherosclerotic burden in type 2 diabetes?
Population
176 T2DM participants from the GADA study
Comparison
Plasma lipid species levels associated with FAI and CAD burden
Design
Cross-sectional analysis
Key result
In 176 T2DM patients, circulating LPE (18:1), LPE (20:4), and LPE (18:2) were independently associated with both pericoronary adipose tissue inflammation and coronary artery disease burden.
Authors
Loading...
LPEs may identify high-risk T2DM patients; hypothesis-generating and should not yet change practice.
Cross-Sectional (n=176)
Are circulating lysophosphatidylethanolamine species associated with pericoronary adipose tissue inflammation and coronary atherosclerotic burden in type 2 diabetes?
Circulating LPE species (18:1, 20:4, 18:2) are identified as potential lipid-inflammatory biomarkers associated with pericoronary adipose tissue inflammation and coronary atherosclerotic burden in patients with type 2 diabetes.
Dai et al. (2026) conducted a cross-sectional in Type 2 diabetes mellitus (n=176). Circulating lysophosphatidylethanolamine (LPE) species was evaluated on Pericoronary adipose tissue (PCAT) inflammation and coronary artery disease (CAD) burden. In 176 T2DM patients, circulating LPE (18:1), LPE (20:4), and LPE (18:2) were independently associated with both pericoronary adipose tissue inflammation and coronary artery disease burden.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: